Prognostic Value of the CALLY Index in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Retrospective Cohort Study
Diagnostics · 03.09.2025 · 15 (17) · 2237
DOI: 10.3390/diagnostics15172237 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diagnostics, online erschienen am 03.09.2025. Verfasst von Hasan Oguz Cetinayak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir 35210, Türkiye. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The hypopharyngeal region is among the most aggressive sites of head and neck squamous cell carcinoma, often presenting at an advanced stage with poor survival outcomes. However, there are only a limited number of biomarkers available to predict the prognosis of this aggressive disease. Recent interest has focused on immunonutritional biomarkers that may improve prognostication. The C-reactive protein–albumin–lymphocyte (CALLY) index has emerged as a composite biomarker integrating systemic inflammation, nutritional status, and immune competence. However, its clinical relevance in hypopharyngeal cancer has not been established.
Methods
This retrospective, single-center study included patients with histologically confirmed hypopharyngeal squamous cell carcinoma treated with definitive chemoradiotherapy between 2010 and 2024. Patients were excluded from the study if they had incomplete laboratory data, had a concomitant malignancy, were undergoing induction chemotherapy, or had diseases affecting inflammatory and immunological markers. The CALLY index was calculated using pre-treatment laboratory values. Receiver operating characteristic (ROC) analysis determined the optimal cut-off value for overall survival (OS). Kaplan–Meier survival estimates and Cox regression analyses were used to assess associations between the CALLY index and progression-free survival (PFS), local recurrence-free survival (LRFS), and OS.
Results
A total of 71 patients were included. The optimal CALLY cut-off was 1.47 (AUC = 0.70, p = 0.006). Patients with a CALLY index ≥ 1.47 had significantly improved median PFS (37 vs. 9 months, p = 0.003), LRFS (39 vs. 9 months, p = 0.002), and OS (61 vs. 11 months, p = 0.002). In multivariate analysis, the CALLY index and T stage remained independent prognostic factors of all three survival outcomes.
Conclusions
The pretreatment CALLY index is a practical, accessible biomarker that independently predicts survival in hypopharyngeal cancer. Its integration into clinical practice may enhance risk stratification and guide individualized management strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir 35210, Türkiye.
- Department of Radiation Oncology, Izmir City Hospital, Izmir 35530, Türkiye.
ORCID-Profile: Hasan Oguz Cetinayak, Volkan Semiz, Rahmi Atıl Aksoy
Zitieren
APA
Cetinayak, H. O., Aydin, B., Semiz, V., Atac Kutlu, E., Basan, U., & Aksoy, R. A. (2025). Prognostic Value of the CALLY Index in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Retrospective Cohort Study. Diagnostics, 15(17), 2237. https://doi.org/10.3390/diagnostics15172237
Vancouver
Cetinayak HO, Aydin B, Semiz V, Atac Kutlu E, Basan U, Aksoy RA. Prognostic Value of the CALLY Index in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Retrospective Cohort Study. Diagnostics. 2025;15(17):2237. doi:10.3390/diagnostics15172237
BibTeX
@article{Cetinayak2025,
author = {Cetinayak, Hasan Oguz and Aydin, Barbaros and Semiz, Volkan and Atac Kutlu, Ece and Basan, Umut and Aksoy, Rahmi Atıl},
title = {Prognostic Value of the CALLY Index in Hypopharyngeal Cancer Treated with Definitive Chemoradiotherapy: A Retrospective Cohort Study},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {17},
pages = {2237},
doi = {10.3390/diagnostics15172237}
}
EUVIMED